Pentoxifylline decreases tumor necrosis factor expression and serum triglycerides in people with AIDS
Article Abstract:
Pentoxifylline may reduce production of tumor necrosis factor (TNF) in AIDS patients. TNF promotes replication of HIV and interferes with the effectiveness of zidovudine (AZT). TNF production was analyzed in 16 patients with advanced AIDS who took 400 milligrams of controlled-release pentoxifylline three times per day for eight weeks. TNF production decreased in 10 patients during treatment with pentoxifylline, was unchanged in four patients and increased in two patients. Average blood levels of triglycerides decreased after treatment with pentoxifylline. Lower blood levels of triglycerides are associated with decreased levels of TNF. No serious side effects occurred among the patients who completed treatment with pentoxifylline. Some patients had mild nausea during the first few days of treatment, and one patient had severe nausea.
Publication Name: Journal of Acquired Immune Deficiency Syndromes
Subject: Health
ISSN: 0894-9255
Year: 1993
User Contributions:
Comment about this article or add new information about this topic:
Pentoxifylline inhibits HIV-1 LTR-driven gene expression by blocking NF-kappa-B action
Article Abstract:
The antiviral drug pentoxifylline (PTX) may interfere with the activity of nuclear factor-kappa-B (NF-kappa-B). NF-kappa-B is a regulatory protein that interacts with the long terminal repeat (LTR) sequence of HIV-1. The LTR is a portion of a viral genome that controls replication. A study examined the effect of PTX on the LTR-driven replication of bacterial genes in human embryo kidney cells transfected with the LTR sequence of HIV-1. Treatment with PTX significantly decreased the interaction of NF-kappa-B with the LTR sequence in activated cells. This decrease was followed by a significant drop in LTR-driven replication of bacterial genes.
Publication Name: Journal of Acquired Immune Deficiency Syndromes
Subject: Health
ISSN: 0894-9255
Year: 1993
User Contributions:
Comment about this article or add new information about this topic:
Tenidap inhibits replication of the human immunodeficiency virus-1 in cultured cells
Article Abstract:
The drug tenidap appears capable of inhibiting HIV reproduction. Tenidap is used to treat rheumatoid arthritis. A study has shown that tenidap inhibited HIV reproduction as measured by p24 antigen in T lymphocyte and monocyte cell lines. The concentration of drug that could inhibit HIV was substantially lower than the typical dosage used in arthritis patients. Although tenidap inhibits the production of interleukin-6 by other blood cells, the effect on HIV reproduction appeared to be independent of interleukin-6 inhibition.
Publication Name: Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology
Subject: Health
ISSN: 1077-9450
Year: 1997
User Contributions:
Comment about this article or add new information about this topic:
- Abstracts: Interleukin-1 expression by neutrophils in rheumatoid arthritis. Receptor expression in synovial fluid neutrophils from patients with rheumatoid arthritis
- Abstracts: Hospitals respond by expanding outside care. Woman cites ADA in bid for experimental treatment. Vermont leaning toward single-payer; budget target set
- Abstracts: Baseline plasma fibrinolysis and its correlation with clinical manifestations in patients with Raynaud's phenomenon
- Abstracts: Directional coronary atherectomy versus balloon angioplasty. Treatment with bivalirudin (Hirulog) as compared with heparin during coronary angioplasty for unstable or postinfarction angina